DASGOO Cross-border e-commerce trading platform

In order to implement the requirements of the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drug Devices" by the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council, the Food and Drug Administration organized the drafting of the "Announcement on Adjusting the Review and Approval of Drug Clinical Trials (Draft for Comment) )", now open for comments and suggestions.

Relevant units and individuals are requested to provide feedback via email before January 14, 2018.

In order to encourage innovation, accelerate the creation of new drugs, and meet the needs of the public, according to the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drug Devices" by the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council (Ding Zi [2017] No. 42), the clinical medicine is optimized Trial review and approval, drawing on international experience, make adjustments to clinical trial review and approval procedures and methods.

The Food and Drug Administration issued a public solicitation of comments on the review and approval